Question 1

What is Opyl’s AI platform and how does it optimise clinical trial design and success predictions?

Accepted Answer

Opyl offers an AI-powered decision support platform, TrialKey, trained on data from over 468,000 clinical trials and 2.69 billion patients. TrialKey utilises biostatistical validation, predictive analytics, and high-fidelity simulations—running up to 100,000 trial scenarios—to predict clinical trial success with an accuracy of over 92%. This enables sponsors and researchers to optimise trial protocols, improve patient recruitment, and reduce costly amendments, ultimately increasing the likelihood of successful drug and device development.

Question 2

How does Opyl improve patient recruitment and engagement for clinical trials?

Accepted Answer

Opyl’s Opin platform leverages AI to analyse social media and digital communities, identifying and engaging motivated patients for clinical trial participation. By using precision recruitment strategies that go beyond traditional doctor-led referrals, Opin enhances patient matching and accelerates enrollment. This approach addresses challenges related to recruitment inefficiencies, improving trial timelines and data quality by connecting sponsors with willing and appropriate participants worldwide.

Question 3

What measurable benefits do organisations gain from using Opyl’s AI solutions in life sciences?

Accepted Answer

Organisations utilising Opyl’s AI platforms experience improved operational efficiency and reduced risk in clinical trials. Benefits include up to 40% acceleration in trial milestones, enhanced patient retention through better recruitment, and more informed decisions based on explainable AI insights into trial variables and success factors. Opyl’s partnership with Innovatrix also integrates trial success predictions into insurance underwriting, enabling risk mitigation and financial optimisation for biotech and pharmaceutical stakeholders.

Useful Links

Our Services

Contact Us